Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
DCGI Suspends Nod to Entod's New Eye Drops Over Unapproved 'claims'
Details : PresVu (pilocarpine) is a muscarinic cholinergic receptor agonist (M1/M3) used on the eye to treat Presbyopa.
Brand Name : PresVu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2024
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ENTOD’s PresVu Eye Drops Gain DCGI Approval
Details : PresVu (pilocarpine) is a muscarinic cholinergic receptor agonist (M1/M3) used on the eye to treat Presbyopa.
Brand Name : PresVu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
Lead Product(s) : Pilocarpine Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine,Benzalkonium Chloride
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Entod Pharmaceuticals Launches CYCLOTEARS Eye Drops
Details : Cyclotears 0.05% eye drops contains cyclosporin which belongs to the group of medicines called Immunosuppressants. It is used to treat severe dry eye syndrome (keratoconjunctivitis sicca) in children and in adolescents (aged between 4-18 years).
Brand Name : Cyclotears
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 04, 2023
Lead Product(s) : Cyclosporine,Benzalkonium Chloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Entod Pharma Gets DCGI Nod to Conduct Phase III Study of 0.05% Atropine
Details : Myatro (atropine eye drop)
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 31, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Saffron Extract
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MACUSAFF (Crocin), Manufactured from 100 percent DNA certified Persian origin natural saffron extract improves retinal flicker sensitivity, blood flow, protects RGC, reduce intraocular pressure and supports natural mechanisms of the eye is introduce in I...
Brand Name : Macusaff
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 21, 2022
Lead Product(s) : Saffron Extract
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Entod Pharma to Launch Generic Molnupiravir Under Brand Molentod in India
Details : DCGI approved the launching of MOLENTOD™ (Molnupiravir), based on the review of clinical data of molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and who have high risk of progression of the disease including hospitalisation ...
Brand Name : Molentod
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 05, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?